Search Results



Find ALL words: john theurer cancer center
Found 16 documents, showing 1 - 10.
[1-10]  [11-16]  [Next >>]
Help
  1. Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. | 2013 ASCO Annual Meeting Abstracts
    ... , Philadelphia, PA; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... , PA; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ...-category: Kidney Cancer Category: Genitourinary (Nonprostate) Cancer Meeting: 2013 ASCO Annual ...
    ... (Nonprostate) Cancer Meeting: 2013 ASCO Annual Meeting Abstract No: TPS4595 Citation: J Clin ...
    ... Cancer Center, Washington, DC; Beth Israel Deaconess Medical Center, Boston, MA; ...
    ... Deaconess Medical Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; ...
    ...-Kettering Cancer Center, New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; ...

  2. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). | 2013 ASCO Annual Meeting Abstracts
    ... , Kristen Hege; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; University ...
    ... Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Institut ...
    ... University Medical Center, Hackensack, NJ; Institut Gustave Roussy, Villejuif, France; Mayo Clinic, ...
    ...-Sinai Medical Center, Los Angeles, CA; University College London Cancer Institute, London, ...

  3. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. | 2013 ASCO Annual Meeting Abstracts
    ... , Tampa, FL; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... M. D. Anderson Cancer Center, Houston, TX; University of California, San Francisco, San ...
    ... ; Fred Hutchinson Cancer Research Center, Seattle, WA; H. Lee Moffitt Cancer Center & Research ...
    ... Cancer Research Center, Seattle, WA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, ...

  4. Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy. | 2013 ASCO Annual Meeting Abstracts
    ... , New York, NY; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... ; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Hofstra North Shore-LIJ School ...
    ... Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; University Of ...

  5. Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. | 2013 ASCO Annual Meeting Abstracts
    ... , Summit, NJ; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... Comprehensive Cancer Center, Sacramento, CA; Emory University Winship Cancer Institute, ...
    ... University Winship Cancer Institute, Atlanta, GA; University of Virginia Medical Center, ...
    ... ; Nebraska Medical Center, Omaha, NE; Institute of Hematology "Serągnoli", University of Bologna, ...
    ... Virginia Medical Center, Charlottesville, VA; Medical University of Vienna, Oncology, Vienna, ...

  6. Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. | 2013 ASCO Annual Meeting Abstracts
    ... Carl Anderson; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... ; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Dana-...
    ... , NJ; Dana-Farber Cancer Institute, Boston, MA; Washington University in St. Louis, St Louis, MO; ...
    ... University Medical Center, Columbus, OH; H. Lee Moffitt Cancer Center & Research Institute, Tampa, ...

  7. Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL). | 2013 ASCO Annual Meeting Abstracts
    ... (s): Anas Younes, John Radford, Stephen Maxted Ansell, Andrea Gallamini, Won Seog Kim, Tatyana A ...
    ... , South Korea; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... Texas MD Anderson Cancer Center, Houston, TX; The Christie Hospital NHS Foundation Trust, ...
    ... ; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; West ...

  8. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. | 2013 ASCO Annual Meeting Abstracts
    ... , Tampa, FL; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... Sinai Medical Center, New York, NY; Ohio State University Medical Center, Columbus, OH; H. ...
    ... University Medical Center, Columbus, OH; H. Lee Moffitt Cancer Center & Research Institute, Tampa, ...

  9. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. | 2013 ASCO Annual Meeting Abstracts
    ... , Ann Arbor, MI; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... Comprehensive Cancer Center, Ann Arbor, MI; University of Chicago, Winooski, VT; The ...
    ... of Chicago Medical Center, Chicago, IL; Poznan University of Medical Sciences, Poznan, Poland; ...
    ... Cancer Center, Ann Arbor, MI; University of Chicago, Winooski, VT; The University of ...
    ... Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Mount Sinai ...

  10. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). | 2013 ASCO Annual Meeting Abstracts
    ... , Columbus, OH; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, ...
    ... ASCO | Conquer Cancer Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of ...
    ... Foundation | Cancer.Net | Journal of Clinical Oncology | Journal of Oncology Practice Home ...
    ... ; Dana-Farber Cancer Institute, Boston, MA; Department of Internal Medicine, Division of ...
    ... Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Emory ...
    ... University Medical Center, Hackensack, NJ; Emory University School of Medicine, Atlanta, GA; ...
    ... Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard ...
Results Pages:  [1-10]  [11-16]  [Next >>]